Compare VALU & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VALU | CGEN |
|---|---|---|
| Founded | 1931 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.5M | 270.4M |
| IPO Year | 1995 | 2001 |
| Metric | VALU | CGEN |
|---|---|---|
| Price | $32.95 | $2.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 1.2K | ★ 545.2K |
| Earning Date | 03-16-2026 | 05-18-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | ★ 8.91 | N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $36,257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | $17.01 | ★ N/A |
| Revenue Growth | ★ 1.08 | N/A |
| 52 Week Low | $32.16 | $1.30 |
| 52 Week High | $40.50 | $3.24 |
| Indicator | VALU | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 33.33 |
| Support Level | N/A | $1.46 |
| Resistance Level | $38.30 | $2.35 |
| Average True Range (ATR) | 0.77 | 0.19 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 8.16 | 1.61 |
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.